Reported preliminary Phase 1 findings from a Single Ascending Dose (SAD) trial that suggest single subcutaneous injections of CTI-1601 were well tolerated at doses up to 100 mg in Friedreich'sataxia (FA) patients
Placebo-controlled Phase 1 trials in FA patients remain on track for topline data in Q2 2021
Thursday, March 4, 2021
Larimar Therapeutics Reports Fourth Quarter and Full Year 2020 Operating and Financial Results
BioSpace.com, Published: Mar 04, 2021.
